Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
CYP2D6 genotyping and use of antidepressants in breast cancer patients: Test development for clinical application
Metabolic Brain Disease, Volume 27, No. 3, Year 2012
Notification
URL copied to clipboard!
Description
Approximately 25 % of clinically important drugs and numerous environmental carcinogens are metabolised by CYP2D6. Variation in the CYP2D6 gene and concomitant use of tamoxifen (TAM) with certain antidepressants may increase recurrence risk in breast cancer patients due to reduced enzyme activity. In this study we determined the appropriateness of adding CYP2D6 genotyping to the breast cancer genetic testing options already available in South Africa, which include BRCA mutation screening and transcriptional profiling to assess estrogen receptor (ER) status. A total of 114 South African breast cancer patients, including 52 Caucasian and 62 Coloured (Mixed ancestry), and 63 Caucasian control individuals were genotyped for the most common inactivating allele (CYP2D6*4, rs3892097) previously identified in the CYP2D6 gene. In the initial validation data set consisting of 25 Caucasian and 62 Coloured patients, the CYP2D6*4 allele frequency was significantly higher in Caucasian compared to Coloured patients (24 % vs. 3 %, p≤0.001), similar to previous findings in the general South African population. Extended CYP2D6 genotyping was subsequently performed in an implementation data set of 27 Caucasian breast cancer patients, to determine the prevalence of depression and use of antidepressants in a clinical setting. A medical history of depression and/or use of antidepressants was reported in 37 % (10/27) of these breast cancer patients genotyped for CYP2D6*4. This translational research study has led to increased awareness among clinicians of the potential benefits of CYP2D6 genotyping to facilitate prevention of cumulative risk in a high-risk genetic subgroup of breast cancer patients considered for concomitant treatment of TAM and antidepressants that may reduce enzyme function. © Springer Science+Business Media, LLC 2012.
Authors & Co-Authors
Merwe, Nicole Van Der
South Africa, Stellenbosch
Stellenbosch University
Bouwens, Christianne S.H.
South Africa, Stellenbosch
Stellenbosch University
Pienaar, Rika
South Africa, Parow
Panorama Medi-clinic
van der Merwe, Lize
South Africa, Tygerberg
South African Medical Research Council
South Africa, Bellville
University of the Western Cape
Yako, Yandiswa Yolanda
South Africa, Stellenbosch
Stellenbosch University
Geiger, Dieter H.
South Africa, Stellenbosch
Stellenbosch University
Kotze, Maritha J.
South Africa, Stellenbosch
Stellenbosch University
Statistics
Citations: 7
Authors: 7
Affiliations: 4
Identifiers
Doi:
10.1007/s11011-012-9312-z
e-ISSN:
15737365
Research Areas
Cancer
Genetics And Genomics
Mental Health
Substance Abuse
Study Design
Cross Sectional Study
Study Locations
South Africa